Home

arrow iconNewsarrow iconarrow icon

TRAP Laws a Major and Escalating Cause of Concern in Modern Fertility Treatments

TRAP Laws a Major and Escalating Cause of Concern in Modern Fertility Treatments

Targeted regulations of abortion providers - TRAP Laws increasingly show serious, documented maternal health complications and access barriers, specifically for the vulnerable population conceiving via advanced fertility treatments.

By FertilityIn

18 Feb 2026

4 min read

Couple consulting a doctor about fertility treatment options during a medical appointment

Couple consulting a doctor about fertility treatment options during a medical appointment

In the United States, states with restrictive abortion laws are increasingly associated with poorer maternal health outcomes, particularly among patients who conceive through fertility treatments, according to new research.


A study published in JAMA Health Forum by researchers at Oregon Health & Science University (OHSU) found that states enforcing targeted regulations of abortion providers (TRAP laws) report significantly higher rates of serious maternal health complications among patients who used fertility treatments, compared with states without such restrictions.


Says an assistant professor of obstetrics and gynecology in the OHSU School of Medicine and also the lead author of the study, Dr. Molly Kornfield, "People with highly planned and desired pregnancies may not be who we typically think of when we discuss the impacts of abortion restrictions, but their health and safety are being considerably impacted." 


She added, "These data prove what we already know: abortion restrictions don’t exist in a vacuum - they affect everyone who needs reproductive health care." 


Patients who have already gone through infertility diagnoses go on to face bloated risks at the time of pregnancy and childbirth. These risks include hemorrhage, fetal growth restriction, gestational diabetes, preterm birth, stillbirth, and also, in certain cases, hysterectomy. The OHSU team is examining if the limits on access to comprehensive reproductive care also worsen those risks. Making use of a retrospective, population-based group design, researchers went on to evaluate maternal and neonatal health outcomes of over 400,000 births that were conceived via fertility treatments between 2012 and 2021. 


The analysis suggested a statistically prominent rise in major maternal complications within states that practice TRAP laws. These included some higher rates when it comes to blood transfusions, ICU admissions, sudden hysterectomies, and uterine rupture, all of which can be pretty life-threatening and may also permanently affect the patient's ability to carry pregnancies in the future.  Although this study did not point toward a single cause for the disparities, the researchers confirmed many systemic factors that are likely to contribute.  


These factors include closure of fertility clinics in the states that follow restrictions, departure of abortion providers due to passage of restrictive laws, and also a countrywide shortage of OB/GYNs - conditions that both limit access to on-time and specialized care when complications crop up. 


Notably, the findings are already going ahead and influencing how clinicians counsel the patients, especially the ones who are pregnant post the fertility treatment.

  

Researchers have noted that the providers may as well advise the patients to take more precautions on travel at the time of pregnancy, due to the erratic availability when it comes to emergency reproductive care across the state lines. 


This is rather more concerning for people already experiencing barriers and discrimination in the health care system, such as people of color and immigrants, as well as LGBTQ+ individuals, confirmed the study authors. They further added that these legal restrictions can bloat up the presently existing inequities when it comes to maternal health. 


A resident physician in the department of obstetrics and gynecology at OHSU and also a co-author of the study, Dr. Samuel Melville, opines that the outcomes do highlight the interconnected nature as far as reproductive health services are concerned. 


He further adds, “We’re lucky to be living and practicing in Oregon, where we’re able to offer evidence-based, full-scope reproductive health care, but sadly this isn’t the case in so many areas." "If we want to truly support the health of children and families, we need to acknowledge that safe reproduction includes abortion care." 

40 views

Share

FertilityIn

Send Enquiry for this Story

Related Articles

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.

ART

1 min read

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.

ART

1 min read

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.

ART

1 min read

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.

ART

1 min read

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.

ART

1 min read

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.

ART

1 min read

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.

ART

1 min read

Landing Page Image

Subscribe to our Newsletter

Stay updated with the latest news, expert insights, and exclusive offers delivered straight to your inbox. Join our community today!

Email Address